Three companies made the cut
An integrated AI-and-experimentation platform, multiple pipeline programs and substantial post-IPO runway support the strongest new Candidate profile.
TRB-061 produced reproducible Treg activation in Phase 1a. Patient-level efficacy in atopic dermatitis is the next major test.
Revenue, backlog and Tennessee atomizer capacity establish traction; profitable production and capital intensity remain the gates.
Theme is the starting point. Evidence determines the classification.
Six evidence families
Structural theme, business quality, growth and traction, competitive position, financial durability and market confirmation.
Lifecycle, not ratings
Candidate and Watching describe the maturity of the evidence package. They are not buy, sell or hold recommendations.
Price moves score zero
Post-IPO performance can attract research attention, but it contributes zero points to the Emerging Score.
The October 24 Watchlist
Select a company for its thesis, SNF Lens, scorecard, evidence ledger and review history.
Read the complete October research
Download the report for the complete cohort, six expanded profiles, company thesis checks, confirmation calendar and methodology.
Download the 17-Page PDFResearch and monitoring context only. Not investment advice, a price target, forecast return, trade signal or recommendation to buy, sell or hold any security.
